Equities Analysts Issue Forecasts for MDxHealth Q3 Earnings

MDxHealth SA (NASDAQ:MDXH - Free Report) - Equities researchers at William Blair cut their Q3 2025 earnings per share (EPS) estimates for MDxHealth in a report issued on Thursday, May 15th. William Blair analyst A. Brackmann now forecasts that the company will post earnings per share of ($0.11) for the quarter, down from their previous forecast of ($0.09). The consensus estimate for MDxHealth's current full-year earnings is ($1.15) per share. William Blair also issued estimates for MDxHealth's Q4 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.50) EPS, Q1 2026 earnings at ($0.09) EPS, Q2 2026 earnings at ($0.09) EPS, Q3 2026 earnings at ($0.09) EPS and FY2026 earnings at ($0.33) EPS.

MDxHealth Stock Performance

Shares of MDxHealth stock traded down $0.02 during trading on Monday, hitting $2.04. 60,462 shares of the company's stock traded hands, compared to its average volume of 86,155. MDxHealth has a 1 year low of $1.35 and a 1 year high of $3.50. The business has a 50-day simple moving average of $1.67 and a 200-day simple moving average of $1.85. The company has a debt-to-equity ratio of 3.14, a current ratio of 1.54 and a quick ratio of 1.45. The stock has a market capitalization of $96.47 million, a P/E ratio of -1.34 and a beta of 1.32.

MDxHealth (NASDAQ:MDXH - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.06). MDxHealth had a negative net margin of 49.52% and a negative return on equity of 1,077.84%. The business had revenue of $24.29 million for the quarter, compared to analysts' expectations of $22.62 million.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Renaissance Technologies LLC lifted its holdings in MDxHealth by 715.2% in the fourth quarter. Renaissance Technologies LLC now owns 123,100 shares of the company's stock valued at $292,000 after acquiring an additional 108,000 shares during the period. Perkins Capital Management Inc. lifted its holdings in MDxHealth by 31.6% in the fourth quarter. Perkins Capital Management Inc. now owns 983,475 shares of the company's stock valued at $2,331,000 after acquiring an additional 236,100 shares during the period. Samjo Management LLC lifted its holdings in MDxHealth by 130.9% in the fourth quarter. Samjo Management LLC now owns 1,824,312 shares of the company's stock valued at $4,324,000 after acquiring an additional 1,034,312 shares during the period. Oppenheimer & Co. Inc. lifted its holdings in MDxHealth by 100.0% in the fourth quarter. Oppenheimer & Co. Inc. now owns 20,000 shares of the company's stock valued at $47,000 after acquiring an additional 10,000 shares during the period. Finally, AWM Investment Company Inc. lifted its holdings in MDxHealth by 11.1% in the fourth quarter. AWM Investment Company Inc. now owns 4,721,290 shares of the company's stock valued at $11,189,000 after acquiring an additional 471,290 shares during the period.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.